OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Figlin on the Evolving Treatment Landscape of Renal Cell Carcinoma

February 15th 2020

Robert A. Figlin, MD, discusses the evolving treatment landscape of renal cell carcinoma (RCC).

Dr. Crew on Treatment in Favorable-Risk HER2+ Breast Cancer

February 14th 2020

Katherine Crew, MD, MS, discusses treatment for patients with favorable-risk early-stage HER2-positive breast cancer.

Dr. Putcha on the Results of the AI EMERGE Trial in CRC

February 14th 2020

Girish Putcha, MD, PhD, discusses the results of the AI EMERGE trial (NCT03688906) in colorectal cancer.

Dr. Randall on the SAFETY Trial in Soft Tissue Sarcoma

February 14th 2020

R. Lor Randall, MD, FACS, discusses the SAFETY trial (NCT03944798) in soft tissue sarcoma.

Dr. Corcoran on Targeting HER2 Amplification in CRC

February 14th 2020

Ryan B. Corcoran, MD, PhD, discusses the presence of HER2 amplification in metastatic colorectal cancer.

Biomarker Research in Ovarian Cancer

February 14th 2020

Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.

Dr. Awan on Time-Limited Treatments in CLL

February 14th 2020

Farrukh Awan, MD, discusses the need for time-limited treatments in patients with chronic lymphocytic leukemia.

Dr. Pal on Cohort Findings of COSMIC-021 Trial in mCRPC

February 14th 2020

Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.

Dr. Usmani on Situations that Indicate the Need for Immediate Treatment in R/R Multiple Myeloma

February 14th 2020

Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.

Dr. Bose on Treating Progression in Patients With Myelofibrosis

February 14th 2020

Prithviraj Bose, MD, discusses treatment for patients with progressive myelofibrosis.

Dr. Goy on Combinations With Novel Agents in Relapsed/Refractory MCL

February 14th 2020

Andre Goy, MD, MS, discusses the utility of combinations with novel agents in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Hamilton on the Results of the KATHERINE Trial in HER2+ Breast Cancer

February 14th 2020

Erika P. Hamilton, MD, discusses the superiority of ado-trastuzumab emtansine (T-DM1; Kadcyla) in the phase III KATHERINE study.

Dr. Cheng on the Goals of the GENTleMEN Trial in Prostate Cancer

February 14th 2020

Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.

Dr. Eward on the Unmet Need for Novel Agents for TGCT and Sarcoma

February 14th 2020

William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.

Dr. Moore on Results of the FORWARD I/GOG 3011 Trial in Ovarian Cancer

February 14th 2020

Kathleen Moore, MD, discusses topline findings from the phase III FORWARD I/GOG 3011 trial in ovarian cancer.

Nuances of Immunotherapy-Related AEs in Melanoma

February 14th 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses the nuances of immunotherapy related adverse events in melanoma.

Dr. Gupta on BLASST-1 Results in Muscle-Invasive Bladder Cancer

February 13th 2020

Shilpa Gupta, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the results of the phase II BLASST-1 trial, which is evaluating nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer who are undergoing cystectomy.

Dr. Kansagra on Remaining Questions With CAR T-Cell Therapy in Multiple Myeloma

February 13th 2020

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

Dr. Berger on Chemotherapy Delivery Options in Ovarian Cancer

February 13th 2020

Jessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.

Dr. Andreadis on Antibody-Drug Conjugates in DLBCL

February 13th 2020

Charalambos (Babis) Andreadis, MD, MSCE, discusses the utility of antibody-drugs conjugates in diffuse large B-cell lymphoma.